Tilray | TRLY - Debt


Tilray reported $640.95M in Debt for its fiscal quarter ending in June of 2022.





Debt Change Date
Acasti Pharma USD 0 0 Sep/2024
Akebia Therapeutics USD 46.51M 7.82M Mar/2025
Alaunos Therapeutics USD 10.99M 5.78M Mar/2023
Aurora Cannabis CAD 23.86M 76.48M Mar/2026
Avita Medical AUD 46.05M 1.46M Dec/2025
Canopy Growth CAD 278.71M 19.38M Mar/2026
Cronos Group USD 1.31M 198K Mar/2026
Dianthus Therapeutics USD 1.36M 79K Mar/2026
Divis Laboratories Ltd INR 70M 30M Mar/2026
Ionis Pharmaceuticals USD 1.91B 425.5M Jun/2026
IQVIA Holdings USD 16.24B 408M Jun/2026
Knight Therapeutics CAD 77.91M 28.33M Dec/2025
Moderna USD 1.3B 7M Mar/2026
Organigram Holdings CAD 8.2M 554K Mar/2026
Organon & Co USD 8.57B 75M Mar/2026
Revvity USD 3.35B 48.03M Mar/2026
Tectonic Therapeutic USD 876K 115K Dec/2024
Tilray USD 640.95M 35.17M Jun/2022
Viatris USD 13.35B 993.3M Jun/2026
Xeris Pharmaceuticals USD 258.55M 899K Mar/2026
Zealand Pharma A/S 414M 8.23M Mar/2026